Free Trial
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Aligos Therapeutics logo
$9.12 -0.54 (-5.59%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$8.94 -0.18 (-2.03%)
As of 03/28/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Key Stats

Today's Range
$8.88
$9.76
50-Day Range
$9.12
$34.24
52-Week Range
$6.76
$46.80
Volume
59,246 shs
Average Volume
174,715 shs
Market Capitalization
$55.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00
Consensus Rating
Buy

Company Overview

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Remove Ads

Aligos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

ALGS MarketRank™: 

Aligos Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 204th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aligos Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aligos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aligos Therapeutics are expected to decrease in the coming year, from ($10.36) to ($11.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aligos Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aligos Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aligos Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aligos Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.93% of the float of Aligos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aligos Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aligos Therapeutics has recently increased by 10.09%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aligos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aligos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.93% of the float of Aligos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aligos Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aligos Therapeutics has recently increased by 10.09%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aligos Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Aligos Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.75% of the stock of Aligos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aligos Therapeutics' insider trading history.
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Stock News Headlines

Aligos Therapeutics files to sell 6.25M shares of common stock for holders
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Aligos Therapeutics presents positive data at APASL2025
Ten option delistings on March 24th
See More Headlines

ALGS Stock Analysis - Frequently Asked Questions

Aligos Therapeutics' stock was trading at $39.84 on January 1st, 2025. Since then, ALGS shares have decreased by 77.1% and is now trading at $9.12.
View the best growth stocks for 2025 here
.

Aligos Therapeutics, Inc. (NASDAQ:ALGS) released its earnings results on Monday, March, 10th. The company reported ($13.08) earnings per share for the quarter, missing analysts' consensus estimates of ($2.63) by $10.45. The company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.43 million. Aligos Therapeutics had a negative trailing twelve-month return on equity of 114.34% and a negative net margin of 1,283.19%.

Aligos Therapeutics's stock reverse split on the morning of Monday, August 19th 2024. The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Aligos Therapeutics (ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager.

Top institutional shareholders of Aligos Therapeutics include Adage Capital Partners GP L.L.C. (9.05%), Trexquant Investment LP (1.92%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.12%) and Avantax Advisory Services Inc. (0.85%).
View institutional ownership trends
.

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Athenex (ATNX), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM).

Company Calendar

Last Earnings
3/10/2025
Today
3/30/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.00
High Stock Price Target
$70.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+667.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-87,680,000.00
Net Margins
-1,283.19%
Pretax Margin
-1,278.62%

Debt

Sales & Book Value

Annual Sales
$3.95 million
Price / Cash Flow
N/A
Book Value
$30.65 per share
Price / Book
0.30

Miscellaneous

Free Float
3,274,000
Market Cap
$55.76 million
Optionable
No Data
Beta
2.52
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ALGS) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners